Who are DHEA (0.5%)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dehydroepiandrosterone (DHEA), DHEA (1.0%), DHEA (0.25%).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dhea-0-5.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

DHEA (0.5%) — Competitive Intelligence Brief

DHEA (0.5%) (DHEA (0.5%)) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prohormone; hormone replacement therapy. Area: Gynecology; Menopause.

phase 3 Prohormone; hormone replacement therapy Androgen receptor; estrogen receptor (via local conversion) Gynecology; Menopause Small molecule Live · refreshed every 30 min

Target snapshot

DHEA (0.5%) (DHEA (0.5%)) — EndoCeutics Inc.. DHEA (dehydroepiandrosterone) is a prohormone that is converted to testosterone and estrogen in peripheral tissues, restoring hormone levels in postmenopausal women.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DHEA (0.5%) TARGET	DHEA (0.5%)	EndoCeutics Inc.	phase 3	Prohormone; hormone replacement therapy	Androgen receptor; estrogen receptor (via local conversion)
Dehydroepiandrosterone (DHEA)	Dehydroepiandrosterone (DHEA)	Boston Children's Hospital	marketed	Steroid hormone / Prohormone	Androgen receptor, Estrogen receptor (indirect via peripheral conversion)
DHEA (1.0%)	DHEA (1.0%)	EndoCeutics Inc.	phase 3	Steroid hormone / Prohormone	Androgen receptor, Estrogen receptor (via peripheral conversion)
DHEA (0.25%)	DHEA (0.25%)	EndoCeutics Inc.	phase 3	Hormone replacement therapy / Prohormone	Estrogen receptor, Androgen receptor (via local conversion)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prohormone; hormone replacement therapy class)

EndoCeutics Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DHEA (0.5%) — Competitive Intelligence Brief. https://druglandscape.com/ci/dhea-0-5. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab